VICTORIA, July 10, 2017 /CNW/ - Emerald Health Therapeutics Inc. (TSXV:EMH) ("Emerald" or the "Company") announced today that its trading symbol on the OTCQX has been changed to EMHTF.
The OTCQX® Best Market is the top tier of financial markets in the OCT Marketplace system. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, and have a professional third-party sponsor introduction. The companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications.
Join us on our journey of making lives better through cannabis science.
Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) operates primarily through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary of the Company and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Botanicals is authorized to produce and sell both dried medical cannabis flowers and medical cannabis oils in Canada. Botanicals currently operates an indoor facility in Victoria, British Columbia, with plans for expansion on a 32-acre property in Metro Vancouver and a joint venture with Village Farms utilizing 25 acres of greenhouse complex in Delta, BC. Botanicals is one of Canada's most medically focused licensed producers, with a team of highly qualified management experienced in pharmaceutical drug discovery, development and distribution. Emerald's vision is to be a leading provider of cannabis products through its production capabilities, proprietary genetics and intellectual property, value-added products and branding, and superb customer experience.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".
We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.
Forward-looking statements include, but are not limited to, statements with respect to legalization of non-therapeutic cannabis sales in Canada; participation in the legalized non-therapeutic cannabis industry; growth in the extract-based market; increased production of cannabis; commercial operations; construction or conversion of production facilities; applications for licensing; obtaining such licenses; commencement of production of cannabis at the Company's facilities; estimates of production capacity at such facilities; contributions of cash to the JV; international opportunities for the Company; commencement of clinical trials; the Company becoming a leading Canadian supplier of cannabis products; expected timing of any of the above matters; and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.
Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, failure of the federal government to approve legislation legalizing sales of non-therapeutic adult-use cannabis; failure to obtain Health Canada and other regulatory approvals; failure to obtain necessary financing; results of production and sale activities; the Company's historical experience with medical marijuana operations; results of scientific research; uninsured risks; regulatory changes; difficulties in construction or in obtaining qualified contractors to complete construction or conversion of facilities; availability of production facilities; timeliness of government approvals and the granting of permits and licenses; changes in prices and costs; actual operating and financial performance of facilities; equipment and processes relative to specifications and expectations; as well as the other risk factors set out in the Company's annual information form and other filing with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.
SOURCE Emerald Health Therapeutics, Inc.
For further information: Sandy Pratt, CFO, Emerald Health Therapeutics, P: 250-818-9838